Physician profile
Ivan Guerrero
NPI 1326016536
$19,752.49
in general payments reported to CMS, 2019-2025
26 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $8,680 · 2021: $1,658 · 2022: $2,186 · 2023: $2,051 · 2024: $1,889 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,610 · Education: $61.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,609.62 |
| Education | $61.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $10,342.92 | 2019-2025 | Dovato, Apretude, Rukobia |
| Gilead Sciences, INC. | $2,967.03 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $1,603.20 | 2019-2025 | Dificid, Pifeltro, Zerbaxa |
| Theratechnologies INC. | $869.41 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $861.94 | 2019-2023 | Symtuza |
| Insmed, INC. | $725.83 | 2019-2025 | Arikayce |
| Abbvie INC. | $705.61 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $214.71 | 2019-2023 | Symtuza |
| Janssen Products, Lp | $214.47 | 2019-2022 | |
| Csl Behring | $198.35 | 2019-2023 | Hizentra |
| Paratek Pharmaceuticals, INC. | $186.14 | 2023-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $158.00 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| Takeda Pharmaceuticals U.S.A., INC. | $153.72 | 2021-2025 | Cuvitru |
| Allergan, INC. | $121.66 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $119.41 | 2023-2025 | Vowst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $91.08 | 2019-2025 | Mytesi |
| Shionogi INC | $47.72 | 2021-2023 | Fetroja |
| Vyera Pharmaceuticals, LLC | $30.02 | 2019 | |
| Nabriva Therapeutics, Plc | $29.21 | 2021 | |
| Pfizer INC. | $20.10 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.44 | 2023 | Rebyota |
| Mayne Pharma Commercial LLC | $18.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.03 | 2023 | |
| Acelrx Pharmaceuticals, INC. | $15.36 | 2020 | |
| Shield Therapeutics INC | $12.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.